The importance of BCL-2 and MYC as therapeutic targets for DLBCL with concomitant overexpression of these two proteins was investigated by Sasaki et al. using two cell lines established from chemoresistant patients. Here, BCL2 is linked to diffuse large B-cell lymphoma.